Skip to content
naulon
Not checkedNot checked for notices yet.

Radiocobalt theranostic applications: current landscape, challenges, and future directions

Alexis M. Sanwick, Ivis F. Chaple

Frontiers in Nuclear Medicine · 2025

doi:10.3389/fnume.2025.1663748 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Radiocobalt-based theranostics has emerged as a promising platform in nuclear medicine that offers dual capabilities for both diagnostic imaging and targeted radionuclide therapy. 55 Co (t 1/2 = 17.53 h, β + = 77%, E γ = 931.1 keV, I γ = 75%) and 58m Co (t 1/2 = 9.10 h, IC = 100%) serve as an elementally matched pair for positron emission tomography and targeted Auger electron therapy, respectively, that enable a more personalized approach to cancer management, where imaging with 55 Co can help to guide and predict therapeutic outcomes for 58m Co therapy. The unique coordination chemistry of cobalt allows for stable complexation with various chelators, enhancing in vivo stability and targeting efficacy when conjugated to biomolecules such as peptides, antibodies, and small molecules. Recent developments in radiolabeling techniques, chelator design, and preclinical evaluations have significantly improved the pharmacokinetic profiles and tumor specificity of radiocobalt-based radiopharmaceuticals. The aim of this mini review is to provide an overview of the recent advancements and applications of radiocobalt isotopes with a particular focus on the production, chelation chemistry, and in vivo targeting of 55 Co- and 58m Co-labelled radiopharmaceuticals over the last 5 years. While challenges still exist in production scalability, dosimetry optimization, and clinical translations, the current trajectory suggests a growing role for radiocobalt-based theranostics in precision oncology.

Abstract licence: CC BY

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.